#1 Clinical Trials Search in Europe

Cenerimod

Cenerimod is an investigational drug being studied as a potential treatment for systemic lupus erythematosus (SLE), a chronic autoimmune disease. This article summarizes key information from clinical trials evaluating the safety, efficacy, and pharmacological properties of cenerimod in patients with SLE and healthy volunteers. The trials aim to determine optimal dosing, assess the drug’s ability to reduce SLE symptoms and disease activity, and evaluate its long-term safety profile.

Table of Contents

What is Cenerimod?

Cenerimod, also known as ACT-334441, is a new oral medication being developed to treat systemic lupus erythematosus (SLE), a chronic autoimmune disease[1]. It is currently undergoing clinical trials to evaluate its effectiveness and safety in patients with moderate to severe SLE[2].

How Cenerimod Works

Cenerimod works by reducing the number of lymphocytes (a type of white blood cell) circulating in the bloodstream[3]. In SLE, the immune system becomes overactive, and lymphocytes play a role in attacking the body’s own tissues. By decreasing the number of these cells, Cenerimod aims to reduce the severity of SLE symptoms and slow down disease progression[4].

Conditions Treated by Cenerimod

The primary condition being targeted by Cenerimod is systemic lupus erythematosus (SLE). SLE is a complex autoimmune disease that can affect various parts of the body, including the skin, joints, kidneys, brain, and other organs. Symptoms can vary widely but often include fatigue, joint pain, skin rashes, and fever[5].

Clinical Trials and Research

Several clinical trials are currently underway to evaluate the efficacy and safety of Cenerimod:

  • A Phase 3 study is investigating the long-term safety and tolerability of Cenerimod in adults with moderate to severe SLE. This study will last for up to 3 years and involve approximately 680 participants[1].
  • Another Phase 3 study is evaluating the efficacy, safety, and tolerability of Cenerimod in adults with moderate to severe SLE. This study will compare Cenerimod to a placebo over a 12-month period[2].
  • A Phase 2b study has been completed, which assessed different doses of Cenerimod (0.5 mg, 1 mg, 2 mg, and 4 mg) compared to placebo in patients with SLE[4].

Dosage and Administration

In the ongoing clinical trials, Cenerimod is being tested at various doses, ranging from 0.5 mg to 4 mg. It is administered as a once-daily oral tablet[2]. The optimal dose for treating SLE is still being determined through these studies.

Potential Side Effects

As Cenerimod is still in clinical trials, the full range of potential side effects is not yet known. However, some areas of special interest being monitored in the trials include[1]:

  • Effects on heart rate and rhythm
  • Changes in blood pressure (both high and low)
  • Cardiovascular effects
  • Liver-related issues
  • Lung-related effects
  • Eye disorders
  • Increased risk of infections
  • Potential for skin and non-skin cancers

It’s important to note that these are potential risks being monitored, and not all patients may experience these side effects. The ongoing clinical trials will help determine the safety profile of Cenerimod[1].

Ongoing Research and Future Prospects

In addition to the main clinical trials for SLE, researchers are also investigating other aspects of Cenerimod:

  • A study is looking at how Cenerimod affects the electrical activity of the heart (QT interval)[6].
  • Another study is examining how Cenerimod interacts with oral contraceptives[6].
  • Researchers are also studying how Cenerimod is processed by the body in people with kidney or liver problems[7][8].

These additional studies will help researchers better understand how Cenerimod works in different situations and patient populations, potentially expanding its use in the future[6][7][8].

Aspect Details
Drug Name Cenerimod (also known as ACT-334441)
Condition Studied Systemic Lupus Erythematosus (SLE)
Administration Oral, once daily
Dosages Studied 0.5 mg, 1 mg, 2 mg, 4 mg
Primary Outcome Measures Change in total lymphocyte count, SLE Responder Index 4 (SRI-4) response
Secondary Outcome Measures BILAG response, changes in specific SLE symptoms, safety assessments
Trial Durations Range from 12 weeks to 3 years
Safety Monitoring Adverse events, heart rate/rhythm, blood pressure, liver function, infections, malignancies
Special Populations Studied Patients with renal or hepatic impairment, Japanese and Caucasian subjects

FAQ

  • What is cenerimod and how does it work? Cenerimod is an investigational oral medication being studied for the treatment of systemic lupus erythematosus (SLE). It works by reducing the number of circulating lymphocytes in the bloodstream, which are immune cells involved in the autoimmune response in SLE.
  • What are the main goals of the cenerimod clinical trials? The main goals are to evaluate the safety, efficacy, and tolerability of cenerimod in patients with moderate to severe SLE. Trials aim to determine optimal dosing, assess the drug's ability to reduce SLE symptoms and disease activity, and evaluate its long-term safety profile.
  • How is the effectiveness of cenerimod measured in the trials? Effectiveness is measured using tools like the SLE Responder Index (SRI-4), which looks at improvements in disease activity scores, physician assessments, and organ involvement. Other measures include changes in lymphocyte counts and specific SLE symptom improvements.
  • What are some of the side effects being monitored? Side effects being closely monitored include effects on heart rate and rhythm, blood pressure changes, liver enzyme abnormalities, infections, and malignancies. The trials are assessing both short-term and long-term safety profiles of cenerimod.
  • How long do the clinical trials for cenerimod typically last? The duration varies, but many trials last 12 months to 3 years. Some studies evaluate short-term effects over a few months, while others assess long-term safety and efficacy for up to 3 years of continuous treatment.

Ongoing Clinical Trials on Cenerimod

  • Study on Long-Term Safety of Cenerimod for Adults with Moderate-to-Severe Systemic Lupus Erythematosus

    Recruiting

    1 1 1
    Investigated drugs:
    Bulgaria Czechia France Germany Greece Poland +3

  • Study on the Effects of Cenerimod for Adults with Moderate to Severe Systemic Lupus Erythematosus

    Not recruiting

    1 1
    Investigated drugs:
    Bulgaria France Greece Poland Romania

  • Study on the Effectiveness and Safety of Cenerimod for Adults with Moderate to Severe Systemic Lupus Erythematosus

    Not recruiting

    1 1
    Investigated drugs:
    Czechia Germany Poland Portugal Spain

Glossary

  • Systemic Lupus Erythematosus (SLE): A chronic autoimmune disease that can affect various parts of the body, including skin, joints, kidneys, brain, and other organs. The immune system attacks the body's own tissues, causing inflammation and damage.
  • Cenerimod: An investigational oral medication being studied for the treatment of systemic lupus erythematosus. It works by reducing the number of circulating lymphocytes in the bloodstream.
  • Lymphocytes: A type of white blood cell that is part of the immune system. In SLE, reducing lymphocyte counts may help control the autoimmune response.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body, including their mechanisms of action and the relationship between drug concentration and effect.
  • SLE Responder Index 4 (SRI-4): A composite measure used to assess improvement in SLE symptoms and disease activity. It includes changes in disease activity scores, physician assessments, and organ involvement.
  • SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000, a tool used to measure disease activity in SLE patients.
  • BILAG: British Isles Lupus Assessment Group index, a comprehensive assessment tool used to measure disease activity in different organ systems affected by SLE.
  • Physician's Global Assessment (PGA): A visual analog scale used by physicians to assess overall disease activity in SLE patients.
  • Adverse Events: Any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.

References